Tibet AIM Pharm. Inc.

002826

CNE100002C39

Pharmaceuticals

End-of-day quote Shenzhen S.E. Other stock markets 06:00:00 2024-04-25 pm EDT			5-day change	1st Jan Change
8.62 ^CNY	+1.29%		+8.70%	-27.38%

Apr. 26	Tibet Aim Pharm. Inc. Proposes Final Dividend for 2023	CI
Apr. 25	Tibet AIM Pharm. Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Tibet AIM Pharm. Inc. authorizes a Buyback Plan.

October 25, 2023

The Board of Directors of Tibet AIM Pharm. Inc. has authorized a buyback plan on October 26, 2023.

Latest news about Tibet AIM Pharm. Inc.

Tibet Aim Pharm. Inc. Proposes Final Dividend for 2023	Apr. 26	CI
Tibet AIM Pharm. Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	Apr. 25	CI
Tranche Update on Tibet AIM Pharm. Inc.'s Equity Buyback Plan announced on October 30, 2023.	Apr. 01	CI
Tranche Update on Tibet AIM Pharm. Inc.'s Equity Buyback Plan announced on October 30, 2023.	Jan. 02	CI
Tibet AIM Pharm. Inc. announces an Equity Buyback for CNY 100 million worth of its shares.	23-10-29	CI
Tibet AIM Pharm. Inc. Reports Earnings Results for the Nine Months Ended September 30, 2023	23-10-29	CI
Tibet AIM Pharm. Inc. authorizes a Buyback Plan.	23-10-25	CI
Tibet AIM Pharm. Inc. Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-22	CI
Tibet AIM Pharm. Inc. Announces Final Profit Distribution Plan to Be Implemented on A Shares for the Year 2022, Payable on 07 July 2023	23-06-30	CI
Tibet AIM Pharm. Inc. Approves Cash Dividend for 2022	23-05-19	CI
Tibet Aim Pharm. Inc. Proposes Final Cash Dividend for the Year 2022	23-04-27	CI
Tibet AIM Pharm. Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-04-26	CI
Tibet AIM Pharm. Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-16	CI
Tibet Aim Pharm Chairman Resigns; Successor Named	23-02-12	MT
Tibet Aim Pharm Unit to Buy 21% Stake in US Medtech Firm Pier 88 Health for $6 Million	23-02-12	MT
Tibet AIM Pharm. Inc. Reports Earnings Results for the Nine Months Ended September 30, 2022	22-10-27	CI
Tibet AIM Pharm. Inc. Reports Earnings Results for the Half Year Ended June 30, 2022	22-08-24	CI
Tibet Aim Pharm. Inc. Announces 2021 Final Profit Distribution Plan to Be Implemented (A Shares) for the Year 2021, Payable on 8 July 2022	22-07-01	CI
Tibet AIM Pharm. Inc. Approves 2021 Profit Distribution Plan	22-05-19	CI
Tibet AIM Pharm. Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022	22-04-27	CI
Tibet AIM Pharm. Inc. Proposes Final Cash Dividend for the Year 2021	22-04-22	CI
Tibet AIM Pharm. Inc. Reports Earnings Results for the Full Year Ended December 31, 2021	22-04-08	CI
Tibet AIM Pharm. Inc. Reports Earnings Results for the Nine Months Ended September 30, 2021	21-10-24	CI
Tibet AIM Pharm. Inc. Approves the Election of Non-Independent Directors, Independent Directors and Non-Employee Supervisors	21-09-14	CI
Tibet Aim Pharm. Inc. Reports Earnings Results for the Half Year Ended June 30, 2021	21-08-25	CI

TIBET AIM PHARM INC is a China-based company principally engaged in the research, design, manufacture and distribution of chemical drugs and Chinese patent medicine. The Companyâs products include self-manufacturing medicine and third-party medicine. Self-manufacturing medicine includes miglitol tablets, hongjinxiaojie tablet, aceclofenac enteric-coated tablets, montmorillonite powder, as well as domperidone tablets, among others. Its third-party medicine includes gualoupi injection, nalmefene hydrochloride injection, oral liquid for children, cefotaxime sodium for injection, as well as carbetocin injection. The Company distributes its products within domestic market and to overseas markets.

Sector

Pharmaceuticals

Calendar

2024-05-17 - Annual General Meeting

More about the company

Income Statement Evolution

More financial data

Sector Other Pharmaceuticals

	1st Jan change	Capi.
TIBET AIM PHARM. INC.	-27.38%	227M
ELI LILLY AND COMPANY	+25.83%	661B
NOVO NORDISK A/S	+27.00%	566B
JOHNSON & JOHNSON	-6.76%	352B
MERCK & CO., INC.	+20.34%	332B
ABBVIE INC.	+3.00%	283B
ASTRAZENECA PLC	+13.09%	231B
NOVARTIS AG	+5.46%	200B
ROCHE HOLDING AG	-9.61%	195B
AMGEN INC.	-6.26%	145B